Mainga Hamaluba/Lancet Infect Dis

COVID-19 mortality in Africa and Asia - Authors' reply.Bejon P Agweyu A Oyier I Hamaluba M Kamuya D Kinyanjui S Barasa E
Lancet Infect Dis, (2025). 25:e440

Rethinking the evidence on COVID-19 in Africa.Bejon P Agweyu A Ochola-Oyier LI Hamaluba M Kamuya D Kinyanjui S Barasa E
Lancet Infect Dis, (2025). 25:e463-e471

Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in HIV-infected people in Kenya (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial.Kimathi D Juan-Giner A Orindi B Grantz KH Bob NS Cheruiyot S Hamaluba M Kamau N Fall G Dia M Mosobo M Moki F Kiogora K Chirro O Thiong'o A Mwendwa J Guantai A Karanja HK Gitonga J Mugo D Ramko K Faye O Sanders EJ Grais RF Bejon P Warimwe GM
Lancet Infect Dis, (2023). 23:974-982

Is triple artemisinin-based combination therapy necessary for uncomplicated malaria?.van der Pluijm RW Peto TJ Hamaluba M Callery JJ Tripura R White NJ Dondorp AM
Lancet Infect Dis, (2022). 22:765-766

Arterolane-piperaquine-mefloquine versus arterolane-piperaquine and artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a single-centre, open-label, randomised, non-inferiority trial.Hamaluba M van der Pluijm RW Weya J Njuguna P Ngama M Kalume P Mwambingu G Ngetsa C Wambua J Boga M Mturi N Lal AA Khuroo A Taylor WRJ Goncalves S Miotto O Dhorda M Mutinda B Mukaka M Waithira N Hoglund RM Imwong M Tarning J Day NPJ White NJ Bejon P Dondorp AM
Lancet Infect Dis, (2021). 21:1395-1406